Methotrexat Medac

Methotrexate, the active ingredient in Methotrexat Medac, is an antimetabolite (folate antagonist) presented as a sterile solution for intra‑arterial, intramuscular, intrathecal use. It treats certain cancers, rheumatoid arthritis and psoriasis in adults.

GNH USA supplies Methotrexat Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is employed across several disease families, primarily as a disease‑modifying agent in autoimmune disorders and as a cytotoxic agent in malignancies.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: inhibits leukemic cell proliferation. - Osteosarcoma: impedes tumor growth and metastasis. - Other malignancies: provides antineoplastic activity in various solid tumours.

Methotrexate may cause a range of adverse reactions, from mild to severe, depending on dose, route and patient factors.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common after administration. - Fatigue: persistent tiredness reported by many patients. - Mucositis: inflammation and ulceration of the oral mucosa. - Elevated liver enzymes: mild transaminitis detectable on labs. - Alopecia: temporary hair thinning or loss. - Cytopenias: mild reductions in white blood cells or platelets.

Serious or Rare Side Effects: - Severe liver toxicity: potential for fibrosis or cirrhosis. - Pulmonary fibrosis: interstitial lung disease with dyspnea. - Bone marrow suppression: profound pancytopenia increasing infection risk. - Renal failure: impaired clearance leading to toxicity. - Life‑threatening infections: due to immunosuppression. - Secondary malignancies: rare development of new cancers.

Methotrexate requires careful monitoring and specific safety measures before and during therapy. - Pregnancy contraindication: avoid use in pregnancy (Category X). - Renal function monitoring: assess creatinine clearance prior to each dose. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Hematologic monitoring: regular complete blood counts to detect cytopenias. - Concomitant NSAID caution: avoid or limit NSAIDs due to increased toxicity risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several drugs that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate plasma levels. - Penicillins and other β‑lactam antibiotics: may reduce renal clearance. - Sulfonamides: potentiate bone marrow suppression. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect renal excretion. - Trimethoprim‑sulfamethoxazole: increased risk of hematologic toxicity. - High‑dose folic acid supplementation: may diminish therapeutic effect.